Background: The diagnosis of antiphospholipid syndrome (APS) relies predominantly on the laboratory measure-ment of antiphospholipid antibodies (aPLs). We attempt to verify the analytical performance of anticardiolipin antibodies (aCL) IgA/IgG/IgM and anti-β2-glycoprotein I antibodies (aβ2GPI) IgA/IgG/IgM on a high-throughput automated immunoassay platform. Methods: Limit of blank (LOB), limit of detection (LOD), imprecision, and linearity were calculated according to the corresponding Clinical and Laboratory Standards Institute (CLSI) guidelines protocols. The biological refer-ence intervals (RIs) were verified in healthy individuals. Results: The LoB of aCL IgA/IgG/IgM and aβ2GPI IgA/IgG/IgM were 0.000, 1.200, 0.200, and 0.400, 1.250, 0.100, respectively. The LoD were 0.093, 1.715, 0.337 and 0.547, 2.174, 0.185 CU, respectively. All the within-run CVs and total CVs were less than the criterion at 10%. The linear analysis showed a good correlation between the pre-dictive values and observed values with correlation coefficients greater than 0.99. Conclusions: The BIO-FLASH automated chemiluminescent analyzer performed well in measuring aPLs. © 2021 Verlag Klinisches Labor GmbH. All rights reserved.